deltatrials
Completed PHASE3 NCT03730662

A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk

Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)

Sponsor: Eli Lilly and Company

Conditions Type 2 Diabetes Mellitus
Interventions Insulin Glargine Tirzepatide
Updated 26 times since 2018 Last updated: Jan 21, 2022 Started: Nov 20, 2018 Primary completion: Jan 22, 2021 Completion: Apr 22, 2021

This PHASE3 trial investigates Type 2 Diabetes Mellitus and is currently completed. Eli Lilly and Company leads this study, which shows 26 recorded versions since 2018 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Feb 2019 · 31 days · monthly snapshot~Feb 2019 – ~Mar 2019 · 28 days · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~May 2019 · 30 days · monthly snapshot~May 2019 – ~Jun 2019 · 31 days · monthly snapshot~Jun 2019 – ~Jul 2019 · 30 days · monthly snapshot~Jul 2019 – ~Aug 2019 · 31 days · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Oct 2019 · 30 days · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Jan 2020 · 31 days · monthly snapshot~Jan 2020 – ~Feb 2020 · 31 days · monthly snapshot~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~Jan 2021 · 10 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~May 2021 · 2 months · monthly snapshot~May 2021 – ~Jun 2021 · 31 days · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Mar 2022 · 6 months · monthly snapshot~Mar 2022 – ~Jul 2024 · 28 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Dec 2025 · 3 months · monthly snapshot~Dec 2025 – present · 4 months · monthly snapshot

Change History

26 versions recorded

  1. Dec 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2025 — Dec 2025 [monthly]

    Completed PHASE3

  3. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  5. Mar 2022 — Jul 2024 [monthly]

    Completed PHASE3

▶ Show 21 earlier versions

  1. Sep 2021 — Mar 2022 [monthly]

    Completed PHASE3

  2. Jun 2021 — Sep 2021 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  3. May 2021 — Jun 2021 [monthly]

    Active Not Recruiting PHASE3

  4. Mar 2021 — May 2021 [monthly]

    Active Not Recruiting PHASE3

  5. Jan 2021 — Mar 2021 [monthly]

    Active Not Recruiting PHASE3

  6. Mar 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  7. Feb 2020 — Mar 2020 [monthly]

    Recruiting PHASE3

  8. Jan 2020 — Feb 2020 [monthly]

    Recruiting PHASE3

  9. Dec 2019 — Jan 2020 [monthly]

    Recruiting PHASE3

  10. Nov 2019 — Dec 2019 [monthly]

    Recruiting PHASE3

  11. Oct 2019 — Nov 2019 [monthly]

    Recruiting PHASE3

  12. Sep 2019 — Oct 2019 [monthly]

    Recruiting PHASE3

  13. Aug 2019 — Sep 2019 [monthly]

    Recruiting PHASE3

  14. Jul 2019 — Aug 2019 [monthly]

    Recruiting PHASE3

  15. Jun 2019 — Jul 2019 [monthly]

    Recruiting PHASE3

  16. May 2019 — Jun 2019 [monthly]

    Recruiting PHASE3

  17. Apr 2019 — May 2019 [monthly]

    Recruiting PHASE3

  18. Mar 2019 — Apr 2019 [monthly]

    Recruiting PHASE3

  19. Feb 2019 — Mar 2019 [monthly]

    Recruiting PHASE3

  20. Jan 2019 — Feb 2019 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  21. Dec 2018 — Jan 2019 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Nov 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Eli Lilly and Company
Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , Afula, Israel , Alicante, Spain , Almería, Spain , Alzira, Spain , Anaheim, United States , Arecibo, Puerto Rico , Arkhangelsk, Russia , Atlanta, United States , Baia Mare, Romania and 175 more locations